look news india
Sanjivani Parenteral Limited: Headquartered in Mumbai and having pharmaceutical companies in Navi Mumbai and Dehradun, Sanjivani Parenteral Limited specializes in the manufacturing and distribution of high quality parenteral and oral solid products. We primarily offer products in CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergy therapeutic/product areas with strong research and development (RDN) support.
Commenting on the results, Ashwani Khemka, Chairman and Managing Director, Sanjivani Parenteral Limited, said, “We are pleased to report a strong performance for the first quarter of the financial year 2024-25, which reflects our commitment to high-quality pharma products. During the quarter under review, our oral products segment showed exceptional performance and the injectables segment showed consistent results. However, we believe in the long-term strategy and will continue to invest in research and development (R&D) and innovation. Our focus on export markets has proven fruitful, contributing significantly to our overall revenues. Our diversified portfolio and strategic operations have enabled us to achieve significant revenue growth year-on-year despite challenges in a dynamic global environment.
Revenue from operations grew 31 percent year-on-year to Rs. 165 million. While EBITDA margin rose to 14.7 percent and net profit (PAT) grew 11 percent to Rs. 17 million.
Looking at segment-wise performance, revenue in injectables grew 4.6 percent year-on-year to Rs. 61.1 million and revenue in orals grew 116.6 percent year-on-year to Rs. 99.3 million. Further, revenue from nutraceuticals grew 61.3 percent year-on-year to Rs. 4.0 million.
Looking at the market-wise performance, exports (including export incentives) accounted for 87.2 per cent of the total revenue, the domestic market accounted for the remaining share and the major markets of CIS (including Russia), Middle East & Africa and Latin America accounted for 88.2 per cent of the total revenue of Rs. 145.04 million.
